期刊文献+

胆汁酸TGR5受体在疾病中的研究进展

Research progress of bile acid TGR5 receptor in diseases
原文传递
导出
摘要 TGR5受体是G蛋白偶联受体家族(G protein-coupled receptors,GPCRs)中的成员。TGR5受体在人类和动物中的许多组织如肾、肝、胃、小肠、肺等中都处于高表达,其中在胎盘和脾中的表达最高。TGR5不仅是胆汁酸的受体,也可以被其他的一些合成激动剂所激活介导一系列的信号通路,参与机体的生理和病理过程,如4-苯氧基-烟酰胺或4-苯氧基-嘧啶-5-甲酰胺化合物、6α-乙基-23(S)-甲基-胆酸(6-EMCA,INT-777)等。本文主要综述了TGR5受体在二型糖尿病、肥胖、炎症、癌症及肝脏再生等疾病发生发展中的作用。 TGR5 receptor is a member of G protein-coupled receptors(G protein-coupled receptors,GPCRs).The TGR5 receptor is highly expressed in many tissues of humans and animals,such as kidney,liver,stomach,intestine,lung,but its expression is the highest in the placenta and spleen.TGR5 is not only a bile acids receptor but also can be activated by other synthetic agonists to mediate a lot of signaling pathways in the physiological and processes,such as 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compound,6α-ethyl-23(S)-methyl-cholic acid(6-EMCA,INT-777),etc.This article mainly focuses on summarizing the role of TGR5 receptors in the development of diseases such as type 2 diabetes,obesity,inflammation,cancer,and liver regeneration.
作者 祁有朝 李培锋 QI You-chao;LI Pei-feng(College of Veterinary,Medicine,Inner Mongolia Agricultural University,Hohhot 010018,China;Key Laboratory of Clinical Diagnosis and Treatment Techniques for Animal Disease,Ministry of Agriculture,Hohhot 010018,China)
出处 《中国兽医科学》 CAS CSCD 北大核心 2019年第12期1580-1585,共6页 Chinese Veterinary Science
基金 国家自然科学基金面上项目(31272605)
关键词 TGR5受体 二型糖尿病 肥胖症 炎症 癌症 肝脏再生 TGR5 receptor T2D obesity inflammation cancer liver regeneration
  • 相关文献

参考文献3

二级参考文献60

  • 1Ross R. The pathogenesis of atherosclerosis:a perspective for the 1990s[J].Nature,1993,(6423):801-809.
  • 2Katagiri H,Yamada T,Oka Y. Adiposity and cardiovascular disorders:disturbance of the regulatory system consisting of humoral and neuronal signals[J].Circulation Research,2007,(01):27-39.
  • 3Glass CK,Witztum JL. Atherosclerosis:the road ahead[J].Cell,2001,(04):503-516.doi:10.1016/S0092-8674(01)00238-0.
  • 4Steinberg D. Atherogenesis in perspective:hypercholesterolemia and inflammation as partners in crime[J].Nature Medicine,2002,(11):1211-1217.
  • 5Kugiyama K,Kerns SA,Morrisett JD. Impairment of endotheliumdependent arterial relaxation by lysolecithin in modified low-density lipoproteins[J].Nature,1990,(6262):160-162.
  • 6Stiko-Rahm A,Hultgardh-Nilsson A,Regnstrom J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells[J].Arteriosclerosis and Thrombosis,1992,(09):1099-1109.
  • 7Yui S,Sasaki T,Miyazaki A. Induction of murine macrophage growth by modified LDLs[J].Arteriosclerosis and Thrombosis,1993,(03):331-337.
  • 8Steinberg D,Parthasarathy S,Carew TE. Beyond cholesterol.Modifications of low-density lipoprotein that increase its atherogenicity[J].New England Journal of Medicine,1989,(14):915-924.
  • 9Shoji T,Nishizawa Y,Fukumoto M. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and antioxLDL antibody levels in healthy subjects[J].Atheroclerosis,2000,(01):171-177.
  • 10Fraley AE,Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease[J].Current Opinion in Lipidology,2006,(05):502-509.doi:10.1097/01.mol.0000245255.40634.b5.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部